cas 876343-10-1|| where to buy 4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine

Название продукции:4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine

IUPAC Name:4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine

Упаковочная единица	Доступно для заказа	Цена ($)
CM104043-5g	in stock	şǆȋ
CM104043-10g	in stock	Ǡƴœ
CM104043-25g	in stock	ǆƴȋ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 876343-10-1 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:876343-10-1; Молекулярная формула:C6H3ClIN3; Точка плавления:-; Smiles-код:ClC1=C2C=C(I)NC2=NC=N1; Плотность:

: Номер в каталоге:CM104043; Молекулярная масса:279.47; Точка кипения:; Номер Mdl:MFCD11518919; Хранение:-20°C

: Pyrrolopyrimidines; Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.

: BMF-219; Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.